Cambridge, MA--In a breaking news report released by CNBC last night, Moderna stock surged some 16 percent in after-hours trading on the company's announcement that its potential vaccine to prevent Covid-19 produced a “robust” immune response in all 45 patients in its early stage human trial. The CNBC report was based on newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine. Dow Jones futures also jumped on the hopeful news.
Also in the CNNBC report:
“These Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly support the choice of 100 µg in a prime and boost regimen as the optimal dose for the Phase 3 study,” Moderna’s chief medical officer, Tal Zaks [shown above in a video interview], said in a statement. “We look forward to beginning our Phase 3 study of mRNA-1273 this month to demonstrate our vaccine’s ability to significantly reduce the risk of COVID-19 disease.”